

Review of NICE Technology Appraisal Guidance No 82; Pimecrolimus and tacrolimus for atopic eczema

Appendix 1: Proposal comment summary table

Respondent	Response to proposal	Details	Comment from Technology Appraisal
Astellas Pharma (tacrolimus)	Disagree	"We have just received approval for a new maintenance indication for Protopic, supported by clinical data such that it may warrant a review of Guidance No 82."	Comment noted. The new maintenance indication has been taken into account for this review. Considering that the population reflected in the licence extension will already have this topical cream to treat their condition on an intermittent basis; implementation of any guidance on secondary prophylaxis for the same population will therefore be challenging. For this reason, a review of the existing tacrolimus guidance incorporating an appraisal of the licence extension would not provide value for the NHS.
British Association of Dermatologists	Agree		Comment noted
Cochrane Skin Group, Centre of Evidence-based Dermatology	Agree		Comment noted
Novartis Pharmaceuticals (pimecrolimus)	No comment		Noted.
Royal College of Nursing	No objection		Comment noted
Royal College of Physicians	Agree		Comment noted

No response received from:

Consultees	Commentators (no right to submit or appeal)	Commentators (no right to submit or appeal)
<u>Patient/carer groups</u> <ul style="list-style-type: none"> • Action Against Allergy • Action for Sick Children • Age Concern England • Allergy UK • Black Health Agency • Changing Faces • Chinese National Healthy Living Centre • Confederation of Indian Organisations • Counsel and Care • Equalities National 	<u>General</u> <ul style="list-style-type: none"> • Age Concern Cymru • Board of Community Health Councils in Wales • British National Formulary • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency (MHRA) • National Public Health Service for Wales 	<u>Comparator manufacturers (contd)</u> <ul style="list-style-type: none"> • Galpharm Healthcare (hydrocortisone) • GlaxoSmithKline (hydrocortisone, betamethasone valerate, clobetasone butyrate, fluticasone propionate, clobetasol propionate) • GP Pharma (fluocinolone acetonide, fluocinonide) • Meadow Laboratories

Consultees	Commentators (no right to submit or appeal)	Commentators (no right to submit or appeal)
<p>Council</p> <ul style="list-style-type: none"> • Help the Aged • Muslim Council of Great Britain • Muslim Health Network • National Eczema Society • Skin Care Campaign • South Asian Health Foundation • Specialised Healthcare Alliance • WellChild <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association for Services to the Elderly • British Dermatological Nursing Group • British Epidermo-Epidemiology Society • British Skin Foundation • Community Practitioners and Health Visitors Association • National Association of Primary Care • Primary Care Dermatology Society • Royal College of General Practitioners • Royal College of Paediatrics and Child Health • Royal Pharmaceutical Society • Royal Society of Medicine – Intellectual Disabilities Forum • United Kingdom Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • Westminster PCT • Warrington PCT • Welsh Assembly Government 	<ul style="list-style-type: none"> • NHS Confederation • NHS Purchasing and Supply Agency • NHS Quality Improvement Scotland • Scottish Medicines Consortium <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • Actavis (hydrocortisone) • Alliance Pharmaceuticals (hydrocortisone) • Astellas Pharma (hydrocortisone, hydrocortisone butyrate) • BCM Specials (hydrocortisone) • Bell Sons & Co. (hydrocortisone) • Biorex Laboratories (hydrocortisone) • Celltech (betamethasone valerate) • Chemidex (hydrocortisone) • Co-Pharma (hydrocortisone) • Derma UK (fluocinolone acetonide, fluocinonide) • Dermal Laboratories (hydrocortisone, betamethasone valerate) • Diomed Developments (hydrocortisone) • Fabre (clobetasol propionate) • Galderma (hydrocortisone, clobetasol propionate) 	<p>(fluocortolone, diflucortolone valerate)</p> <ul style="list-style-type: none"> • Novartis Pharmaceuticals (hydrocortisone) • Pliva Pharma (alclometasone dipropionate) • Reckitt Benckiser Healthcare UK (hydrocortisone) • Roussel Laboratories (hydrocortisone) • Sandoz Ltd (hydrocortisone) • Schering Plough (betamethasone dipropionate, mometasone furoate) • Teva Pharmaceutical Industries (hydrocortisone) • Thornton & Ross (hydrocortisone) • Typharm (fludroxycortide) • UCB Pharma (betamethasone valerate) • Waymade (hydrocortisone) • Wockhardt UK (hydrocortisone) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Policy Research Institute on Ageing and Ethnicity • Skin Research Centre • Skin Treatment & Research Trust <p><u>Assessment team</u></p> <ul style="list-style-type: none"> • Assessment group tbc • National Coordinating Centre for Health Technology Assessment <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Women and Children